Crossref
How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?
AME Clinical Trials Review · 2024
DOI: 10.21037/actr-23-35 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Charlotte De Bondt und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Bondt, C. D., & Schil, P. V. (2024). How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-35
Vancouver
Bondt CD, Schil PV. How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-35
BibTeX
@article{Bondt2024,
author = {Bondt, Charlotte De and Schil, Paul Van},
title = {How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?},
journal = {AME Clinical Trials Review},
year = {2024},
doi = {10.21037/actr-23-35}
}
EUVIMED